Zhang Ning, Song Yanan, Huang Zheyong, Chen Jing, Tan Haipeng, Yang Hongbo, Fan Mengkang, Li Qiyu, Wang Qiaozi, Gao Jinfeng, Pang Zhiqing, Qian Juying, Ge Junbo
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
Biomaterials. 2020 Oct;255:120168. doi: 10.1016/j.biomaterials.2020.120168. Epub 2020 Jun 8.
Stem cell-derived extracellular vesicles (EVs) have been demonstrated to be effective in heart repair and regeneration post infarction. However, the poor homing efficiency and low yields of these therapeutics remain the major obstacles before they can be used in the clinic. To improve the delivery efficiency of EVs to ischemia-injured myocardium, we modified mesenchymal stem cell (MSC)-derived EVs with monocyte mimics through the method of membrane fusion. Monocyte mimic-bioinspired MSC-EVs (Mon-Exos) exhibited enhanced targeting efficiency to injured myocardium by mimicking the recruitment feature of monocytes after MI/RI, thus contributing to these exclusive adhesive molecules on monocyte mimics, particularly the Mac1/LFA1-ICAM-1 interaction. Through this strategy, Mon-Exos were shown to promote endothelial maturation during angiogenesis and modulate macrophage subpopulations after MI/RI, consistent with MSC-Exos biofunctions, and eventually improve therapeutic outcomes in cardiac function and pathohistology changes after treatments in a mouse MI/RI model. Ultimately, this strategy might provide us with a better way to assess the effects of stem cell EVs and offer additional techniques to help clinicians better manage regenerative therapeutics for ischemic heart diseases.
干细胞衍生的细胞外囊泡(EVs)已被证明在心肌梗死后的心脏修复和再生中有效。然而,这些治疗方法的归巢效率低和产量低仍然是其应用于临床之前的主要障碍。为了提高EVs向缺血损伤心肌的递送效率,我们通过膜融合方法用单核细胞模拟物修饰间充质干细胞(MSC)衍生的EVs。单核细胞模拟物仿生MSC-EVs(Mon-Exos)通过模拟心肌梗死/再灌注损伤后单核细胞的募集特征,表现出对损伤心肌的靶向效率增强,这归因于单核细胞模拟物上的这些独特粘附分子,特别是Mac1/LFA1-ICAM-1相互作用。通过这种策略,Mon-Exos被证明在血管生成过程中促进内皮细胞成熟,并在心肌梗死/再灌注损伤后调节巨噬细胞亚群,这与MSC-Exos的生物功能一致,并最终改善小鼠心肌梗死/再灌注损伤模型治疗后心脏功能和病理组织学变化的治疗效果。最终,这种策略可能为我们提供一种更好的方法来评估干细胞EVs的效果,并提供额外的技术来帮助临床医生更好地管理缺血性心脏病的再生治疗。